Sixty Degree Capital reposted this
Excited to have joined Biotech CEO Sisterhood and Deloitte this week for a fantastic discussion on how AI is reshaping healthcare and life sciences. Thank you for bringing together such an engaged community. I'm grateful to my fellow panelists, Najat Khan, PhD, and Mani Mohindru, our moderator, Shikha J., and Erika Smith for organizing such a wonderful event. As a healthcare investor, I've had a front-row seat to AI's rapid evolution over the past few years. What has become increasingly clear is that AI is no longer simply accelerating drug discovery—it is transforming how we discover, develop, evaluate, and ultimately deliver healthcare. One theme that resonated throughout our discussion is that the winners won't simply have the best AI models. They'll combine deep scientific expertise, high-quality proprietary data, and a clear path to clinical impact. AI is an incredibly powerful enabler, but biology remains the ultimate test. The opportunity ahead is enormous. I believe we're only at the beginning of a new era where AI and biology will increasingly converge to improve patient outcomes and redefine the future of healthcare. Thank you again to everyone who attended. I left the event even more optimistic about what's ahead for our industry!
The next generation of biotech leaders will be bilingual — fluent in biology and fluent in AI. Not one or the other. Both. That was the headline of a discussion this week convened by the Biotech CEO Sisterhood and Deloitte on AI in life sciences and healthcare, moderated by Shikha J. with panelists Mani Mohindru, Cheryl Kuai, Ph.D, CFA, and Najat Khan, PhD. Three takeaways: 1. This is not a tools upgrade. It's a structural shift in how the industry discovers, develops, and decides. Every biotech leader now needs to understand where this technology is going. 2. The industry will always need scientists. But they will operate differently, moving from producing and managing data to interrogating it. That skill, not the data itself, is the new advantage. 3. In silico data is now table stakes. Every company will have it. Building the path from in silico to validated asset is what makes it meaningful. The leaders building this fluency now won't just adapt to the next era of biotech. They'll define it. Thank you to our panelists and to the Sisterhood members in the room. Thank you to Biotech CEO Sisterhood members Julia Owens, Erika Smith, Cristina Larkin, Christine D. Baker, and Abigail Jenkins. Plus Deloitte's Mike Kellert, CPA, MBA, Michael Lombardo, and Jeff Ellis. #BiotechCEOSisterhood #BiotechLeadership #AIinLifeSciences